Difference between revisions of "Pentostatin (Nipent)"
m |
|||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Purine (adenosine) analog, inhibitor of adenosine deaminase (ADA), causes elevated intracellular levels of dATP, and inhibits ribonucleotide reductase, which interferes with DNA synthesis. Pentostatin can also inhibit RNA synthesis and has been observed to cause DNA damage. ADA enzymatic activity is greater in T-cell malignancies compared to B-cell malignancies. Exact mechanism of action in hairy cell leukemia is not fully understood.<ref name="insert">[http:// | + | Class/mechanism: Purine (adenosine) analog, inhibitor of adenosine deaminase (ADA), causes elevated intracellular levels of dATP, and inhibits ribonucleotide reductase, which interferes with DNA synthesis. Pentostatin can also inhibit RNA synthesis and has been observed to cause DNA damage. ADA enzymatic activity is greater in T-cell malignancies compared to B-cell malignancies. Exact mechanism of action in hairy cell leukemia is not fully understood.<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=4565 Pentostatin (Nipent) package insert]</ref><ref>[[Media:Pentostatin.pdf|Pentostatin (Nipent) package insert (locally hosted backup)]]</ref><ref>[https://www.pfizerinjectables.com/products/Pentostatin Nipent manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
| − | <br>Extravasation: | + | <br>Extravasation: [[neutral]] |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| Line 19: | Line 17: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 10/11/1991: Initial FDA approval | * 10/11/1991: Initial FDA approval | ||
| + | |||
| + | ==Also known as== | ||
| + | 2'-deoxycoformycin or dCF. | ||
==References== | ==References== | ||
| Line 26: | Line 27: | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
[[Category:Intravenous chemotherapy]] | [[Category:Intravenous chemotherapy]] | ||
| + | [[Category:Neutral chemotherapy]] | ||
[[Category:Antimetabolites]] | [[Category:Antimetabolites]] | ||
Revision as of 21:06, 23 April 2017
General information
Class/mechanism: Purine (adenosine) analog, inhibitor of adenosine deaminase (ADA), causes elevated intracellular levels of dATP, and inhibits ribonucleotide reductase, which interferes with DNA synthesis. Pentostatin can also inhibit RNA synthesis and has been observed to cause DNA damage. ADA enzymatic activity is greater in T-cell malignancies compared to B-cell malignancies. Exact mechanism of action in hairy cell leukemia is not fully understood.[1][2][3]
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Hairy cell leukemia
- Waldenström macroglobulinemia
Patient drug information
- Pentostatin (Nipent) patient drug information (Chemocare)[4]
- Pentostatin (Nipent) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 10/11/1991: Initial FDA approval
Also known as
2'-deoxycoformycin or dCF.